ProGeLife ^Companies

ProGeLife is an organization based in Marseille, France that focuses on developing therapeutic solutions for rare genetic diseases, particularly those characterized by premature or accelerated aging. Founded in 2014, ProGeLife's main goal is to develop drugs for the treatment of these diseases. They specialize in the development of a family of peptides, with a focus on treating Progeria, a rare genetic disease that causes premature aging. The organization's achievements include the discovery of the mutation responsible for Progeria in 2003 by its two founding scientists.